p53 Mutations in C57BL/6J Murine Thymic Lymphomas Induced by 7-Irradiation and TV-Methylnitrosourea

Cancer Research

Volumn 52, Issue 13, 1992, Pages 3791-3795

  Brathwaite, Ormond ^a   Bayona, William ^a   Newcomb, Elizabeth W ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLNITROSOUREA; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME 15; DNA SEQUENCE; FEMALE; GAMMA RADIATION; GENE AMPLIFICATION; GENE MUTATION; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; THYMUS LYMPHOMA; TRISOMY;

ANIMAL; FEMALE; GAMMA RAYS; GENES, P53; GENES, RAS; LYMPHOMA; METHYLNITROSOUREA; MICE; MICE, INBRED C57BL; MUTATION; SUPPORT, U.S. GOV'T, P.H.S.; THYMUS NEOPLASMS; TRISOMY;

EID: 0026696771     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Knudson, A. G. Hereditary cancer, oncogenes and antioncogenes. Cancer Res., 45: 1437-1443, 1985.
2. Peto, R., Roe, F. J. C., Lee, P. N., Levy, L., and Clack, J. Cancer and ageing in mice and man. Br. J. Cancer, 32:411-426,1975.
3. Weinberg, R. A. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res., 49:3713-3721,1989.
4. Barbacid, M. ras genes. Annu. Rev. Biochem., 56:779-827, 1987.
5. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res., 49:4682-4689, 1989.
6. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 351:453-456,1991.
7. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. ras mutations in human cancers. Science (Washington DC), 253:49-53,1991.
8. Bos, J. L., Fearon, E. R., Hamilton, S. R., Verlaan-de Vries, M., van Boom, J. H., van der Eb, A., and Vogelstein, B. Prevalence of ras gene mutations in human colorectal cancer. Nature (Lond.), 327:293-297,1987.
9. Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S., Willson, J. K. V., Hamilton, S., and Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res., 50:7717-7722,1990.
10. Rodenhuis, S., Slebos, R. J., Bolt, A. J. M., Evers, S. G., Mooi, W. J., Wagenaar, S. S., van Bodegom, P. C., and Bos, J. L. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res., 49:5738-5741,1988.
11. Chiba, 1., Takahashi, T., Nau. M. M., D'Amico, D., Curiel, D. T., Mitsudomi, T., Buchhagen, D. L., Carbone, D., Piantadosi, S., Koga, H., Reissman, P. T., Slamon, D. J., Holmes, E. C., and Minna, J. D. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 5:1603-1610,1990.
12. Lehman, T. A., Bennett, W. P., Metcalf, R. A., Welsh, J. A., Ecker, J., Modali, R. V., Ullrich, S., Romano, J. W., Appella, E., Testa, J. R., Gerwin, B. 1., and Harris, C. C. p53 mutations, ras mutations, and 55-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res., 51: 4090-4096,1991.
13. Neri, A., Knowles, D. M., Greco, A., McCormick, F., and Dalla-Favera, R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc. Natl. Acad. Sci. USA, 85:9268-9272,1988.
14. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M., and Dalla-Favera, R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 88:5413-5417, 1991.
15. Hollstein, M. C., Smits, A. M., Galiana, C., Yamasaki, H., Bos, J. L., Mandard, A., Paretensky, C., and Montesano, R. Amplification of epidermal growth factor receptor gene but no evidence of p53 mutations in primary human esophageal cancers. Cancer Res., 48:5119-5123,1988.
16. Hollstein, M. C., Peri, L., Mandard, A. M., Welsh, J. A., Montesano, R., Metcalf, R. A., Bak, M., and Harris, C. C. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent ras base substitutions and absence of p53 mutations. Cancer Res., 51: 4102-4106,1991.
17. Osborne, R. J., Merlo, G. R., Mitsudomi, T., Venesio, T., Liscia, D. S., Cappa, A. P. M., Chiba, I., Takahashi, T., Nau, M. M., Callahan, R., and Minna, J. D. Mutations in the p53 gene in primary human breast cancers. Cancer Res., 51:6194-6198,1991.
18. Halevy, O., Rodel, J. Peled, A., and Oren, M. Frequent p53 mutations in chemically induced murine fibrosarcoma. Oncogene, 6:1593-1600,1991.
19. Gutierrez, M. I., Bhatia, K., Siwarski, D., Wolff, L., Magrath, I. T., Mushin-ski, J. F., and Huppi, K. Infrequent p53 mutation in mouse tumors with deregulated myc. Cancer Res., 52:1032-1035,1992.
20. Ohgaki, H., Hard, G. C., Hirota, N., Maekawa, A., Takahashi, M., and Kleihues, P. Selective mutations in codons 204 and 213 of the p53 gene in rat tumors induced by alkylating JV-nitroso compounds. Cancer Res., 52: 2995-2998,1992.
21. Ben David, Y., Prideaux, V. R., Chow, V., Benchimol, S., and Bernstein, A. Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus. Oncogene, 3: 179-185, 1988.
22. Munroe, D. G., Peacock, J. W., and Benchimol, S. Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles. Mol. Cell. Biol., 70:3307-3313, 1990.
23. Goodrow, T. L., Storer, R. D., Leander, K. R., Prahalada, S. R., van Zweiten, M. J., and Bradley, M. O. Murine p53 intron sequences 5-8 and their use in PCR/direct sequencing analysis of p53 mutations in CD-I mouse liver and lung tumors. Mol. Carcinog., 5:9-15, 1992.
24. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61:759-767,1990.
25. Newcomb, E. W., Steinberg, J. J., and Pellicer, A. ras oncogenes and phenotypic staging in JV-methylnitrosourea-and 7-irradiation-induced thymic lymphomas in C57BL/6J mice. Cancer Res., 48:5514-5521, 1988.
26. McMorrow, L. E., Newcomb, E. W., and Pellicer, A. Identification of a specific marker chromosome early in tumor development in 7-irradiated C57BL/6J mice. Leukemia (Baltimore), 2:115-119,1988.
27. Bienz, B., Zakut-Houri, R., Givol, D., and Oren, M. Analysis of the gene coding for the cellular tumour antigen p53. EMBO J., 3:2179-2183,1984.
28. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A. and Friend, S. H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC), 250:1233-1238,1990.
29. Lavigueur, A., Maltby, V., Mock, D., Rossant, J., Pawson, T., and Bernstein, A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol., 9:3982-3991,1989.
30. Slingerland, J. M., Minden, M. D., and Benchimol, S. Mutation of the p53 gene in human acute myelogenous leukemia. Blood, 77: 1500-1507, 1991.
31. Feinstein, E., Cimino, G., Gale, R. P., Alimena, G., Berthier, R., Kishi, K., Goldman, J., Zaccaria, A., Berrebi, A., and Canaani, E. p53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. USA, 88:6293-6297, 1991.
32. Sugimoto, K., Toyoshima, H.,., Sakai, R., Miyagawa, J., Hagiwara, K., Hirai, H., Ishikawa, F., and Takaku, F. Mutations of the p53 gene in lymphoid leukemia. Blood, 77:1153-1156,1991.
33. Davidoff, A. M., Kerns, B., Iglehart, J. D., and Marks, J. R. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res., 51:2605-2610, 1991.
34. Casson, A. G., Mukhopadhyay, T., Cleary, K. R., Ro. J. Y., Levin B., and Roth, J. A. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res., 51:4495-4499,1991.
35. Guerrero, I., and Pellicer, A. Mutational activation of oncogenes in animal model systems of carcinogenesis. Mutat. Res., 185:293-308, 1987.
36. Newcomb, E. W., Corominas, M., Bayona, W., and Pellicer, A. Multistage carcinogenesis in murine thymocytes: involvement of oncogenes, chromosomal imbalances and T cell growth factor receptor. Anticancer Res., 9: 1407-1416,1989.
37. Sasaki, M. Current status of cytogenetic studies in animal tumors with special reference to nonrandom chromosome changes. Cancer Genet. Cytogenet., 5: 153-172, 1982.
38. Harris, L. J., Lang, R. B., and Marcu, K. B. Non-immunoglobulin-associated DNA rearrangements in mouse plasmacytomas. Proc. Natl. Acad. Sci. USA, 79:4175-4179, 1982.
39. Potter. M. Neoplastic development in B-lymphocytes. Carcinogenesis (Lond.), 11:1-13,1990.
40. Mushinski, J. F., Bauer, S. R., Potter, N., and Reddy, E. P. Increased expression of myc-related oncogene mRNA characterized most BALB/c plasmacytomas induced by pristane or Abelson murine leukemia virus. Proc. Natl. Acad. Sci. USA, 80:1073-1077,1983.
41. Land, H., Parada, L. F., and Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature (Lond.), 304:596-601,1983.
42. Eliyahu, D., Raz, A., Gross, P., Givol, D., and Oren, M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (Lond.), 312:646-649,1984.
43. Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., and Rotter, V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (Lond.), 312:649-651,1984.